Large debt financings continued to contribute to the totals raised by public biotechs in both the U.S. and Europe in 2011, with both Amgen Inc. (NASDAQ:AMGN) and Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) each raising